KR100574307B1 - 건선의 치료를 위한 옥사졸리디논 유도체의 용도 - Google Patents

건선의 치료를 위한 옥사졸리디논 유도체의 용도 Download PDF

Info

Publication number
KR100574307B1
KR100574307B1 KR1020007005366A KR20007005366A KR100574307B1 KR 100574307 B1 KR100574307 B1 KR 100574307B1 KR 1020007005366 A KR1020007005366 A KR 1020007005366A KR 20007005366 A KR20007005366 A KR 20007005366A KR 100574307 B1 KR100574307 B1 KR 100574307B1
Authority
KR
South Korea
Prior art keywords
delete delete
oxazolidinone
acetamide
oxazolidinyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007005366A
Other languages
English (en)
Korean (ko)
Other versions
KR20010032178A (ko
Inventor
도널드 에이치. 바츠
로저 지. 율리히
Original Assignee
파마시아 앤드 업존 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파마시아 앤드 업존 캄파니 엘엘씨 filed Critical 파마시아 앤드 업존 캄파니 엘엘씨
Publication of KR20010032178A publication Critical patent/KR20010032178A/ko
Application granted granted Critical
Publication of KR100574307B1 publication Critical patent/KR100574307B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020007005366A 1997-11-18 1998-11-10 건선의 치료를 위한 옥사졸리디논 유도체의 용도 Expired - Fee Related KR100574307B1 (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US6568997P 1997-11-18 1997-11-18
US60/065,689 1997-11-18
US7129798P 1998-01-16 1998-01-16
US60/071,297 1998-01-16
US7366298P 1998-02-04 1998-02-04
US60/073,662 1998-02-04
US7524798P 1998-02-19 1998-02-19
US60/075,247 1998-02-19
US7767298P 1998-03-12 1998-03-12
US60/077,672 1998-03-12
PCT/US1998/023233 WO1999025344A1 (en) 1997-11-18 1998-11-10 Use of oxazolidinone derivatives for treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020057017426A Division KR100589545B1 (ko) 1997-11-18 1998-11-10 관절염의 치료를 위한 옥사졸리디논 유도체의 용도

Publications (2)

Publication Number Publication Date
KR20010032178A KR20010032178A (ko) 2001-04-16
KR100574307B1 true KR100574307B1 (ko) 2006-04-27

Family

ID=27535698

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020007005366A Expired - Fee Related KR100574307B1 (ko) 1997-11-18 1998-11-10 건선의 치료를 위한 옥사졸리디논 유도체의 용도
KR1020057017426A Expired - Fee Related KR100589545B1 (ko) 1997-11-18 1998-11-10 관절염의 치료를 위한 옥사졸리디논 유도체의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020057017426A Expired - Fee Related KR100589545B1 (ko) 1997-11-18 1998-11-10 관절염의 치료를 위한 옥사졸리디논 유도체의 용도

Country Status (15)

Country Link
EP (1) EP1032386B1 (https=)
JP (1) JP2001522886A (https=)
KR (2) KR100574307B1 (https=)
CN (2) CN1546030A (https=)
AT (1) ATE233092T1 (https=)
AU (1) AU743941B2 (https=)
BR (1) BR9815615A (https=)
CA (1) CA2303961A1 (https=)
DE (1) DE69811717T2 (https=)
DK (1) DK1032386T3 (https=)
ES (1) ES2193592T3 (https=)
NZ (1) NZ504612A (https=)
PT (1) PT1032386E (https=)
SI (1) SI1032386T1 (https=)
WO (1) WO1999025344A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064417A2 (en) 1998-06-05 1999-12-16 Astrazeneca Ab Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
KR20020063851A (ko) * 1999-09-13 2002-08-05 인사이트 비젼 인코포레이티드 안구 감염 예방용 국소 치료제
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
US6451345B1 (en) 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050250709A1 (en) * 2003-12-19 2005-11-10 Bionaut Pharmaceuticals Anti-neoplastic agents, combination therapies and related methods
CN107456442A (zh) * 2016-06-03 2017-12-12 四川赛卓药业股份有限公司 一种噁唑烷酮化合物的亚微乳注射剂及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610265B1 (en) * 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
CA2174107C (en) * 1993-11-22 2005-04-12 Steven J. Brickner Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones

Also Published As

Publication number Publication date
AU743941B2 (en) 2002-02-07
WO1999025344A1 (en) 1999-05-27
ATE233092T1 (de) 2003-03-15
CN1546030A (zh) 2004-11-17
AU1582399A (en) 1999-06-07
BR9815615A (pt) 2000-10-24
EP1032386B1 (en) 2003-02-26
DE69811717D1 (de) 2003-04-03
NZ504612A (en) 2002-08-28
SI1032386T1 (en) 2003-06-30
PT1032386E (pt) 2003-07-31
CA2303961A1 (en) 1999-05-27
KR100589545B1 (ko) 2006-06-19
EP1032386A1 (en) 2000-09-06
DE69811717T2 (de) 2003-10-16
ES2193592T3 (es) 2003-11-01
CN1299281A (zh) 2001-06-13
HK1036591A1 (en) 2002-01-11
DK1032386T3 (da) 2003-05-26
JP2001522886A (ja) 2001-11-20
KR20050100009A (ko) 2005-10-17
KR20010032178A (ko) 2001-04-16
CN1142777C (zh) 2004-03-24

Similar Documents

Publication Publication Date Title
US6040306A (en) Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
WO2002036592A1 (en) Remedies for arachidonic acid-induced skin diseases
CZ55997A3 (en) Co-solvent parenteral formulation of lazaroid
CN111662281B (zh) 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途
AU2011334592C1 (en) Methods of treating eye diseases associated with inflammation and vascular proliferation
KR100574307B1 (ko) 건선의 치료를 위한 옥사졸리디논 유도체의 용도
BR112019018615B1 (pt) Composto antimicrobiano e sua composiqao farmaceutica
TW202106690A (zh) 皮膚型紅斑狼瘡之治療
KR20260011783A (ko) 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비알코올성 지방간 질환 예방 또는 치료용 약학적 조성물
KR102784577B1 (ko) 인간 및 동물에서 알레르기 질환 및 다른 질환의 치료를 위한 말론산의 비스아미드 유도체의 용도
EA003274B1 (ru) Оксазолидиноны в качестве активного вещества при лечении инфекционных глазных болезней
EP1304107A2 (en) Use of oxazolidinines derivatives for treating psoriasis
AU780197B2 (en) Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
JP2025504447A (ja) アスピリン及びその他のｎｓａｉｄの高透過プロドラッグによる心血管疾患の予防又は治療
MXPA00004807A (en) Use of oxazolidinone derivatives for treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
HU225234B1 (en) Use of oxazolidinones for the preparation of a medicament for transdermal delivery
KR970011456B1 (ko) d-2-(6-메톡시-2-나프틸)-프로피온산의 광학활성 유도체와 이것을 함유한 약제학적 조성물
AU9720601A (en) Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
TW201022254A (en) S1P lyase inhibitors for the treatment of cerebral malaria
HK1069768A (en) Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy background of the invention
WO2024023696A1 (en) Dosing regimen for a nlrp3 inhibitor
BRPI0611096A2 (pt) (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)a mino]-1,3-tiazol-4(5h)-ona
JP2025529076A (ja) ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
JPH07503243A (ja) エム・ファーメンタンス感染症の治療
JPH0228113A (ja) 高尿酸血症改善・治療剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090421

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090421

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000